Abstract Context: The relationship between resveratrol and histone acetylation in renal cell carcinoma (RCC) has not yet been reported. Objective: To explore the functional role of resveratrol in RCC. Materials and methods: Functional experiments were performed to determine proliferatio n of ACHN cells with treatment of resveratrol (0, 7.8125, 15.625, 31.25 and 62.5 μg/mL, for 12, 24 and 48 h of culture) or 0.1 μM SAHA. The enzyme activities of MMP-2/-9 were measured by gelatine zymography and histone acetylation by Western blot. Results: When the cells were treated with 15.625, 31.25 and 62.5 μg/mL resveratrol, ACHN cells viability was 73.2 ± 3.5%, 61.4 ± 3.1%, 50.2 ± 4.7% for 12 h, 62.7 ± 4.5%, 52.4 ± 5.5%, 40.2 ± 3.8% for 24 h, and 60.8 ± 3.7%, 39.4 ± 5.1%, 37.6 ± 2.7% for 48 h, and the wound closure (%) of migration was increased from 0.6 to 0.7, 0.85, 0.9 for 12 h and from 0.23 to 0.3, 0.48, 0.59 for 24 h. The invasion rate was 8.5 ± 0.9%, 7.4 ± 0.3% and 5.8 ± 0.6%, and cell cycle was arrested at G1 from 42.5 ± 2.9% to 55.3 ± 5.7%, 59.8 ± 3.4%, 68.7 ± 4.6%. MMP-2/-9 expression (p < 0.05) was inhibited by resveratrol. The protein levels of histone acetylation (p < 0.01) was increased by resveratrol. Discussion and conclusions: Our results suggest that these effects might be related to a high level of histone acetylation, and resveratrol can be considered as an alternative treatment for RCC.

中文翻译：

---

白藜芦醇通过调节组蛋白乙酰化抑制 ACHN 细胞

摘要背景：白藜芦醇与肾细胞癌（RCC）组蛋白乙酰化之间的关系尚未见报道。目的：探讨白藜芦醇在肾细胞癌中的功能作用。材料和方法：进行了功能实验，以确定用白藜芦醇（0、7.8125、15.625、31.25 和 62.5 μg/mL，培养 12、24 和 48 小时）或 0.1 μM SAHA 处理 ACHN 细胞的增殖情况。MMP-2/-9 的酶活性通过明胶酶谱法和组蛋白乙酰化法通过蛋白质印迹法测定。结果：当细胞用 15.625、31.25 和 62.5 μg/mL 白藜芦醇处理时，ACHN 细胞存活率分别为 73.2 ± 3.5%、61.4 ± 3.1%、50.2 ± 4.7%、12 h、62.7 ± 5.5%、± 4.5%、 40.2 ± 3.8% 24 h，60.8 ± 3.7%、39.4 ± 5.1%、37.6 ± 2.7% 48 h，迁移的伤口闭合（%）从0.6增加到0。7、0.85、0.9 为 12 小时，0.23 至 0.3、0.48、0.59 为 24 小时。侵袭率分别为 8.5±0.9%、7.4±0.3% 和 5.8±0.6%，细胞周期在 G1 停滞从 42.5±2.9% 到 55.3±5.7%、59.8±3.4%、68.7±4.6%。MMP-2/-9 表达 (p < 0.05) 被白藜芦醇抑制。白藜芦醇增加了组蛋白乙酰化的蛋白质水平 (p < 0.01)。讨论和结论：我们的结果表明，这些影响可能与高水平的组蛋白乙酰化有关，白藜芦醇可被视为 RCC 的替代疗法。白藜芦醇增加了组蛋白乙酰化的蛋白质水平 (p < 0.01)。讨论和结论：我们的结果表明，这些影响可能与高水平的组蛋白乙酰化有关，白藜芦醇可被视为 RCC 的替代疗法。白藜芦醇增加了组蛋白乙酰化的蛋白质水平 (p < 0.01)。讨论和结论：我们的结果表明，这些影响可能与高水平的组蛋白乙酰化有关，白藜芦醇可被视为 RCC 的替代疗法。